Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 9,6x - 10,6x | 10,1x |
| Selected Fwd EBIT Multiple | 9,2x - 10,1x | 9,6x |
| Fair Value | ₩84.336 - ₩91.986 | ₩88.161 |
| Upside | 5,7% - 15,3% | 10,5% |
| Benchmarks | Ticker | Full Ticker |
| Daewoong Co., Ltd. | A003090 | KOSE:A003090 |
| Boryung Corporation | A003850 | KOSE:A003850 |
| Mezzion Pharma Co.,Ltd. | A140410 | KOSDAQ:A140410 |
| DongKook Pharmaceutical Co., Ltd. | A086450 | KOSDAQ:A086450 |
| Hanall Biopharma Co., Ltd. | A009420 | KOSE:A009420 |
| Chong Kun Dang Pharmaceutical Corp. | A185750 | KOSE:A185750 |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| A003090 | A003850 | A140410 | A086450 | A009420 | A185750 | ||
| KOSE:A003090 | KOSE:A003850 | KOSDAQ:A140410 | KOSDAQ:A086450 | KOSE:A009420 | KOSE:A185750 | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 21.3% | 12.5% | NM- | 3.1% | -57.7% | 5.9% | |
| 3Y CAGR | 15.2% | 19.4% | NM- | 8.1% | -71.6% | 1.6% | |
| Latest Twelve Months | 43.8% | 4.1% | 1.3% | 19.4% | -86.8% | -59.7% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 10.7% | 7.2% | -70.2% | 11.5% | 4.8% | 9.2% | |
| Prior Fiscal Year | 10.7% | 7.9% | -45.7% | 9.1% | 1.3% | 14.8% | |
| Latest Fiscal Year | 14.4% | 6.9% | -166.0% | 9.8% | 0.2% | 6.3% | |
| Latest Twelve Months | 14.4% | 6.9% | -166.0% | 9.8% | 0.2% | 6.3% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 0.80x | 0.60x | 108.21x | 0.75x | 10.06x | 0.57x | |
| EV / LTM EBITDA | 4.6x | 5.3x | -69.8x | 5.6x | 416.9x | 6.4x | |
| EV / LTM EBIT | 5.6x | 8.6x | -65.2x | 7.6x | 6062.2x | 9.0x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -65.2x | 7.6x | 6062.2x | ||||
| Historical EV / LTM EBIT | 9.0x | 10.8x | 19.3x | ||||
| Selected EV / LTM EBIT | 9.6x | 10.1x | 10.6x | ||||
| (x) LTM EBIT | 99,462 | 99,462 | 99,462 | ||||
| (=) Implied Enterprise Value | 953,132 | 1,003,297 | 1,053,461 | ||||
| (-) Non-shareholder Claims * | 153,644 | 153,644 | 153,644 | ||||
| (=) Equity Value | 1,106,776 | 1,156,941 | 1,207,106 | ||||
| (/) Shares Outstanding | 13.2 | 13.2 | 13.2 | ||||
| Implied Value Range | 83,998.98 | 87,806.25 | 91,613.52 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 83,998.98 | 87,806.25 | 91,613.52 | 79,800.00 | |||
| Upside / (Downside) | 5.3% | 10.0% | 14.8% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A003090 | A003850 | A140410 | A086450 | A009420 | A185750 | |
| Enterprise Value | 1,552,445 | 604,551 | 928,826 | 605,580 | 1,394,657 | 897,806 | |
| (+) Cash & Short Term Investments | 264,139 | 191,849 | 28,617 | 90,854 | 24,706 | 302,171 | |
| (+) Investments & Other | 214,304 | 143,826 | 3 | 119,662 | 44,134 | 42,035 | |
| (-) Debt | (717,717) | (168,607) | (1,616) | (80,687) | (1,448) | (188,152) | |
| (-) Other Liabilities | (505,989) | 0 | 0 | (75,499) | 0 | (2,409) | |
| (-) Preferred Stock | 0 | 0 | 0 | (385) | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 807,183 | 771,619 | 955,830 | 659,525 | 1,462,050 | 1,051,450 | |
| (/) Shares Outstanding | 40.9 | 84.0 | 30.0 | 44.0 | 50.8 | 13.2 | |
| Implied Stock Price | 19,740.00 | 9,190.00 | 31,900.00 | 15,000.00 | 28,800.00 | 79,800.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 19,740.00 | 9,190.00 | 31,900.00 | 15,000.00 | 28,800.00 | 79,800.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |